38 active shortage notices across 6 countries · 4 anticipated.
Last updated 17 Sept 2026 · sourced from official medicines regulators
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| Belgium | high | 23 | 19 Feb 2026 | 10 Mar 2027 | FAMHP |
| Netherlands | high | 9 | 30 Mar 2026 | — | CBG-MEB |
| Italy | medium |
| 3 |
| 30 Nov 2024 |
| — |
| AIFA |
| Canada | medium | 1 | 20 Jul 2026 | 9 Feb 2027 | HC |
| Bosnia and Herzegovina | medium | 1 | 26 May 2026 | 31 Aug 2026 | ALMBIH |
| United States | medium | 1 | 8 Sept 2025 | — | FDA |
Yes. As of the latest regulator updates, Sumatriptan has 38 active shortage notices across 6 countries (Belgium, Netherlands, Italy, Canada, Bosnia and Herzegovina, United States). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Sumatriptan shortages to unexpected increases in demand, manufacturing problems, causes not stated by the regulator. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 5 Jun 2026 to 10 Mar 2027, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.